Press release year list 2020 2019 2018 2017
November 16, 2020
Guardant Health, Inc. Prices $1 Billion Convertible Senior Notes Offering
November 16, 2020
Guardant Health, Inc. Announces Proposed Convertible Senior Notes Offering
November 5, 2020
Guardant Health Reports Third Quarter 2020 Financial Results
October 16, 2020
Guardant Health Announces Webcast of Third Quarter Financial Results on November 5, 2020
October 15, 2020
Guardant Health Announces Closing of Public Offering of Common Stock, Including Option to Purchase Additional Shares by Selling Stockholder
October 7, 2020
Guardant Health Announces Pricing of Public Offering of Common Stock by Selling Stockholder
October 6, 2020
Guardant Health Announces Proposed Public Offering of Common Stock by Selling Stockholder
October 5, 2020
Large-Scale Study Shows Guardant360 Liquid Biopsy Accelerates Clinical Trial Enrollment Compared to Tissue Biopsy
September 1, 2020
Guardant Health to Participate in Morgan Stanley 2020 Healthcare Conference
August 24, 2020
Guardant Health Receives FDA Emergency Use Authorization for its Guardant-19 Next Generation Sequencing-Based COVID-19 Test
August 10, 2020
Guardant Health to Participate in Upcoming August Investor Conferences
August 7, 2020
Guardant Health Guardant360® CDx First FDA-Approved Liquid Biopsy for Comprehensive Tumor Mutation Profiling Across All Solid Cancers
August 6, 2020
Guardant Health Reports Second Quarter 2020 Financial Results
July 30, 2020
Guardant Health Announces Collaboration with Radius Health to Develop Liquid Biopsy Companion Diagnostic for Elacestrant
July 21, 2020
Guardant Health Announces Webcast of Second Quarter Financial Results on August 6, 2020
July 8, 2020
Guardant Health Announces Collaboration with Janssen to Develop Liquid Biopsy Companion Diagnostic
June 23, 2020
Guardant Health Launches Real-World Clinical-Genomic Platform to Accelerate Precision Oncology Drug Development
June 22, 2020
Guardant Health Presents Data at AACR Virtual Annual Meeting II Showing Liquid Biopsy Highly Accurate in Detecting Early-Stage Colorectal Cancer
June 16, 2020
Guardant Health Appoints Vijaya Gadde to its Board of Directors
June 8, 2020
Guardant Health Announces Full Exercise of Option and Closing of Public Offering
June 1, 2020
Guardant Health Announces Pricing of Upsized Public Offering
June 1, 2020
Guardant Health Announces Proposed Public Offering of Common Stock
May 29, 2020
Guardant Health to Participate in the William Blair 2020 Growth Stock Conference
May 15, 2020
Guardant Health Data at ASCO and AACR Demonstrates Growing Value of Liquid Biopsy for Precision Oncology in Advanced and Early Stage Cancer
May 7, 2020
Guardant Health Reports First Quarter 2020 Financial Results
May 6, 2020
Guardant Health to Participate in the BofA Securities 2020 Healthcare Conference
May 5, 2020
Guardant Health and Patient Advocacy Groups Join Forces to Raise Awareness of the Importance of Complete Biomarker Testing for Patients with Metastatic Non-Small Cell Lung Cancer
May 2, 2020
Guardant Health Presents Data at DDW Virtual Meeting Highlighting its Early Cancer Detection Program
April 30, 2020
Guardant Health Announces Webcast of First Quarter Financial Results on May 7, 2020
April 9, 2020
Study Shows Guardant360 Test Identifies Predictors of Response to PIK3CA Inhibitors in Women with HR+ Metastatic Breast Cancer
February 24, 2020
Guardant Health Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Full Year 2020 Outlook
February 12, 2020
Guardant Health to Participate in Upcoming Investor Conferences
February 10, 2020
Guardant Health to Report Fourth Quarter and Full Year 2019 Financial Results on February 24, 2020
January 21, 2020
Guardant Health Appoints High-Tech-Veteran Kumud Kalia Chief Information Officer
January 13, 2020
Guardant Health Announces Collaboration With Amgen to Develop a Global Liquid Biopsy Companion Diagnostic for AMG 510 KRAS G12C Inhibitor
January 12, 2020
Guardant Health and NRG Oncology Initiate Randomized Trial to Investigate Circulating Tumor DNA Guided Adjuvant Therapy in Stage II Colon Cancer